Our studies ask important public health and clinical questions about environmental, socioeconomic, lifestyle, genetic, and other factors that may contribute to the incidence, recurrence, and mortality of different cancers, as well as health and quality of life afterward. We collaborate with researchers locally and across the world to reduce the burden of cancer through our work in three key areas of cancer epidemiology research: Etiology, Survivorship, and Intervention.
The CERC is a long-standing research unit comprised of epidemiologists, scientific and administrative support staff, data analysts, IT staff, project coordinators, interviewers, medical record abstractors, and trainees. Research studies focus on identifying the causes of cancer, factors associated with survival, the effects of cancer and cancer treatment on quality of life and overall health and testing strategies for prevention for many different types of cancer including breast, prostate, colorectal, ovarian, endometrial, and testicular cancers.
Addressing research gaps in the molecular subtypes of breast cancer, we are taking a multidisciplinary approach to study the epidemiology and mutational landscapes of basal-like, luminal A, and luminal B tumors.
Funding Agency: DOD
Contact: Sarah Taylor, sataylor@fredhutch.org
Scientists identify differences in the bacterial community in tumors for patients with etiologically-distinct subgroups of colorectal cancer, and how those differences relate to survival.
Funding Agency: National Cancer Institute
Contact: Amanda Phipps, aphipps@fredhutch.org
After identifying early detection biomarkers for each of these cancers, we are conducting phase 2 and phase 3 validation studies directed towards clearly defined clinical applications.
Funding Agency: National Cancer Institute
Contact: Chris Li, cili@fredhutch.org
Using two ovarian cancer case-control studies, scientists are trying to determine why some women develop ovarian tumors and others do not.
Funding Agency: National Cancer Institute
Contact: Holly Harris, hharris@fredhutch.org
Using the Optum Labs/United Healthcare database, investigators review healthcare use patterns of chronic myelogenous leukemia patients treated in the tyrosine kinase inhibitor era.
Funding Agency: American Association for Cancer Research (AACR)
Contact: Nancy Blythe, nblythe@fredhutch.org
ColoCare is a research study for people newly diagnosed with colon or rectal cancer. It includes researchers, doctors, nurses, and patients working together to learn more about improving health after a cancer diagnosis.
Funding Agency: National Cancer Institute
Contact: Kathy Vickers, kvickers@fredhutch.org
Building on the success of PROSPR I, PROSPR II investigators from a variety of disciplines and institutions are conducting research to improve the screening of cervical, colorectal, and lung cancers.
Funding Agency: National Cancer Institute
Contact: Marty Stiller, mstiller@fredhutch.org
Scientists are determining the efficacy of dexrazoxane (DRZ) in reducing anthracycline-related cardiomyopathy among participants in DRZ phase 3 therapeutic trials.
Funding Agency: National Cancer Institute
Contact: Nancy Blythe, nblythe@fredhitch.org
This randomized controlled trial will investigate a 12-week dietary intervention based on the Alternative Healthy Eating Index, examining its effects on pain, quality of life, and inflammatory biomarkers among women with laparoscopically-confirmed endometriosis. The study results will help us identify evidence-based, modifiable, dietary factors that decrease pain and improve quality of life among women with endometriosis.
Funding Agency: National Institutes of Health/NINR
Contact: Nancy Blythe, endostudy@fredhutch.org
Scientists are comparing the echocardiographic changes in left ventricular function and geometry for survivors of childhood cancer who experienced cardiomyopathy to those of survivors who did not.
Funding Agency: National Cancer Institute
Contact: Nancy Blythe, nblythe@fredhutch.org